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Abstract
Introduction: Epidemiological studies underline the fact that obesity represents a significant risk factor for the develop-
ment of several cancers, one of which is cancer of the colon. Moreover, multiple recent data indicate that some adipose
tissue-derived hormones may influence the growth of malignant cells. Leptin, the product of the ob gene, is one of these.
However, the evidence from research is still contradictory regarding the role of leptin in colon cancer. The aim of our study
was to examine the direct effect of leptin at various concentrations (from 105 to 1012 M) when applied alone or jointly with
fluorouracil (the classical cytotoxic drug for colon cancer) at two concentrations (0.25 mg/ml and 2.5 mg/ml) on the growth
of murine Colon 38 cancer cells in vitro.
Material and methods: Colon 38 cancer cells were preincubated in RPMI 1640 medium supplemented with foetal calf
serum for 24 hours. The cells were then cultured for a further 72 hours in the presence of various concentrations of the
substances under examination, applied either alone or jointly. The growth of the Colon 38 cell line was assessed by
a colorimetric kit based on the modified Mosmann method.
Results: We found that leptin increased the growth of murine Colon 38 cancer at concentrations of 106, 107 M and 1010,
1011, 1012 M. Its stimulatory effect was fairly slight, with an increase in cancer growth of 5% to 15% as compared to controls.
As we expected, fluorouracil at both the concentrations examined inhibited the growth of Colon 38 cancer maximally up to
28% (2.5 mg/ml) and 34% (0.25 mg/ml) of controls, with a stronger effect obtained from higher doses. Leptin did not
modulate the cytotoxic effect of fluorouracil applied at the higher concentration (2.5 mg/ml) but, unexpectedly, at concen-
trations of 109 and 1010 M it heightened the cytotoxic effect of fluorouracil given at a lower concentration (0.25 mg/ml).
Conclusions: These data indicate that leptin is involved in the regulation of colon cancer growth and it may even heighten
the cytotoxic effect of fluorouracil.
(Pol J Endocrinol 2007; (58) 1: 26)
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Streszczenie
WstŒp: Z badaæ epidemiologicznych wynika, ¿e oty‡oæ jest istotnym czynnikiem ryzyka rozwoju ró¿nych nowotworów,
miŒdzy innymi równie¿ raka jelita grubego. Ponadto, w wielu badaniach wykazano, ¿e niektóre hormony wywodz„ce siŒ
z tkanki t‡uszczowej wp‡ywaj„ na wzrost komórek nowotworowych oraz moduluj„ inne procesy zwi„zane z karcynogenez„,
jak np. angiogenezŒ. Leptyna, produkt genu ob jest jednym z nich. Celem badaæ by‡a ocena bezporedniego wp‡ywu ró¿nych
stŒ¿eæ leptyny zastosowanej osobno lub razem z fluorouracylem na wzrost mysiej linii raka jelita grubego Colon 38.
Materia‡ i metody: Komórki raka Colon 38 by‡y preinkubowane w medium RPMI 1640 z dodatkiem p‡odowej surowicy
cielŒcej przez 24 godz. NastŒpnie, komórki te by‡y hodowane przez kolejne 72 godz. w obecnoci ró¿nych stŒ¿eæ badanych
substancji. Wzrost raka Colon 38 oceniano, opieraj„c siŒ na zmodyfikowanej kolorymetrycznej metodzie Mosmanna.
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Wyniki: Wykazano, ¿e leptyna stymuluje wzrost raka Colon 38 w stŒ¿eniach 106, 107 M oraz 1010, 1011, 1012 M. Jej dzia‡a-
nie by‡o s‡abe, choæ istotne statystycznie z nasileniem wzrostu tego nowotworu o 515% w porównaniu z grup„ kontroln„.
Jak oczekiwano, fluorouracyl w obu stŒ¿eniach (0,25 mg/ml i 2,5 mg/ml) hamowa‡ wzrost tego nowotworu maksymalnie
do 28% (2,5 mg/ml) i 34% (0,25 mg/ml) grupy kontrolnej. Leptyna nie zmienia‡a cytotoksycznego dzia‡ania fluorouracylu
zastosowanego w wy¿szym stŒ¿eniu (2,5 mg/ml), lecz niespodziewanie w stŒ¿eniach 109 i 1010 M nasili‡a cytotoksyczny
wp‡yw fluorouracylu zastosowanego w ni¿szym stŒ¿eniu (0,25 mg/ml).
Wnioski: Uzyskane wyniki wskazuj„, ¿e leptyna jest regulatorem wzrostu raka jelita grubego, a w wybranych warunkach
nasila cytotoksyczne dzia‡anie fluorouracylu.
(Endokrynol Pol 2007; (58) 1: 26)
S‡owa kluczowe: leptyna, fluorouracyl, rak jelita grubego
Introduction
Colon cancer is a growing problem in our ageing socie-
ty because of its high incidence, morbidity and mortali-
ty. It is usually diagnosed late, at the advanced stages
when surgery is ineffective or even contraindicated.
Thus most diagnosed colon cancers have to be treated
with chemotherapy. Great strides have been made in
the treatment modalities for the advanced stages of this
cancer in the last ten years in association with the intro-
duction of five new drugs (irinotecan  1996, oxalipla-
tin  2002, capecitabine, an oral formulation of fluoro-
uracil  1998; bevacizumab  monoclonal antibody-
targeting vascular endothelial growth factor  2004;
cetuximab  monoclonal antibody targeting epithelial
growth factor receptor  2004). However, the progress
achieved in prolonging average survival is minimal (ap-
proaching a doubling), cure rates remain unchanged
and only drug costs have increased dramatically [1]. The
treatment of this cancer still remains palliative [1]. Thus
the search for new therapeutic options for colon cancer
continues. What we have learned from recent observa-
tion is that the growth of this cancer can be modulated
not only by means of chemotherapy but also through
biotherapy such as cetuximab or bevacizumab [2, 3],
which have recently been approved by the Food and
Drug Administration for use in patients.
A further molecular target for colon cancer appears
to be leptin, since epidemiological studies indicate that
obesity significantly increases the risk of some gastro-
intestinal cancers, including colon cancer [4]. In accor-
dance with this hypothesis some authors suggest that
both hormonal and biochemical factors observed in
obese people, such as elevated levels of leptin, insulin
and insulin-like growth factors, decreased levels of ghre-
lin or elevated levels of triglycerides, low-density lipo-
proteins or prothrombotic and proinflammatory states,
may be implicated in colon carcinogenesis [57]. Lep-
tin, a product of the obese (ob) gene is a 16 kDa cytokine
that was discovered in 1994 as a regulator of body we-
ight and energy balance [8]. This protein hormone is
produced predominantly by white adipocytes and its
circulating concentration in humans is proportional to
the total adipose tissue mass, in other words increased
in obese and decreased in lean subjects [9]. There are
several reports indicating that leptin promotes the
growth of various cancer cell lines, including colon can-
cer cells, by means of stimulation of cancer cell growth,
migration and invasion and through regulation of neo-
angiogenesis [10, 11]. Some authors treat an elevated
leptin level as an independent factor for colon cancer
development [12]. In support of these data, the expres-
sion of leptin receptors (ObR) in colon cancer tissues
and cell lines has been confirmed by immunodetection
[13]. However, the results are not sufficiently concor-
dant and the role of leptin in colon carcinogenesis re-
mains a subject of debate [14]. It has so far been obse-
rved that leptin increases the growth not only of nor-
mal colonic epithelium but also of colon cancer cell li-
nes such as HT-29, LoVo and Coca-2 [1215]. These
stimulatory effects have varied considerably among
various colon cancer cell lines in comparison to con-
trols. However, in vivo leptin did not promote the
growth of colon cancer xenografted in nude mice (Ki-
-67 index in tumour tissues was even inhibited) and did
not stimulate intestinal tumourigenesis in ApcMin/+
mice [14]. Moreover, even in in vitro study leptin was
mitogen only in Apc-deficient (ApcMin/+ IMCE cells)
colonic epithelial cells but not in those expressing wild-
type Apc (Apc+/+ YAMC cells) [15].
Thus the aim of our study was to examine the influ-
ence of leptin, applied alone or in combination with flu-
orouracil, which is the drug of choice for colon cancer,
on the growth of murine Colon 38 cancer cells.
Materials and methods
Murine Colon 38 cancer cells were used in the stu-
dy. The cells were cultured in a culture flask (Nunc Eas
Y flask 25 cm2, NUNC) in the presence of RPMI 1640
medium (Sigma), supplemented with 25 mM Hepes
buffer (Sigma), 4 mM L-glutamine (Sigma), 100 U/ml
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penicillin and 100 µg/ml streptomycin solution (Sigma),
2 g/l sodium bicarbonate (Sigma) and 5% foetal calf se-
rum (FCS, Biochrom) (complete medium). The cells
were routinely cultured in a humidified incubator at
37oC with 5% carbon dioxide. Before confluency the cells
were harvested every 34 days in the presence of pre-
heated (37oC) trypsin-EDTA at a concentration of 0.05%
and 0.02% respectively in Hanks-balanced salt solution
(Trypsin-EDTA, Sigma). Thereafter the cells were col-
lected, rinsed three times in culture medium, centrifu-
ged and seeded in a culture flask (2 × 105 cells/5 ml me-
dium) for the four subsequent days.
After one of the subsequent trypsinisation procedu-
res the cells were suspended in the complete medium
in a concentration of 4 × 105 cells/ml. Next 50 µl aliqu-
ots of the suspension (20 × 103 cells) were seeded into
each well of the culture plate (96 Cell Culture Cluster
Dish, Nunclon MicroWell Plates, NUNC) and preincu-
bated for 24 hours. The cells were then cultured for
a further 72 hours in the presence of various concentra-
tions of the examined substances: mouse leptin [Leptin
(11130) amide (Mouse), BACHEM] in final concentra-
tions of 1051012 M, and Fluorouracil (FU, Roche) in
final concentrations of 0.25 mg/ml or 2.5 mg/ml, applied
either alone or jointly. The control groups were incu-
bated in the complete medium only. Two separate cul-
tures were developed and the cell growth was assessed
by the modified colorimetric Mosmann method, using
the EZ4Y kit (Easy for You, the 4th Generation Non-
Radioactive Cell Proliferation & Cytotoxicity Assay, Bio-
medica Gruppe, Austria, Bellco Biomedica, Poland). This
method is based on the transformation of tetrazolium
salt into coloured soluble formazan via mitochondrial
enzymes, which correlates well with cell proliferation
and viability. The intensity of the reaction was estima-
ted by the measurement of optical density (OD), using
an ELISA reader (l = 450 nm). The data were statistical-
ly analysed by ANOVA and the significance of diffe-
rences between means was determined by LSD (least
significant differences) and presented as a percentage
of the OD of the control group. P < 0.05 was conside-
red the borderline of statistical significance.
Results
In our experimental model leptin enhanced the growth
of Colon 38 cancer cells in 6 out of 9 of the concentrations
examined: 106, 107 M and 1010, 1011, 1012  M (Fig. 1, 2).
The other concentrations of leptin were insufficient to
increase Colon 38 cancer growth effectively. The growth
effect of leptin was somewhat weak and the maximal
stimulation of growth was observed for leptin concen-
trations of 1011 and 1012 M, reaching 115% compared
with controls (Fig. 2). Moreover, we did not observe the
dose-response effect. As we expected, fluorouracil at
both concentrations inhibited the growth of Colon
38 cancer cells and had a greater effect at higher con-
centrations (Fig. 1). Its inhibitory effect was strong, and
it inhibited the growth of Colon 38 cancer maximally
up to 28% (2.5 mg/ml) (Fig. 1) and 34% (0.25 mg/ml)
Figure 1. The effect of leptin (L) applied alone or jointly with fluorouracil (FU) on the growth of Colon 38 cancer cells; C  Control,
*p < 0.05 vs C, ^p < 0.05 vs FU 0.25 µg/ml
Rycina 1. Wp‡yw leptyny (L) stosowanej oddzielnie lub w po‡„czeniu z fluorouracylem (FU) na wzrost komórek raka jelita grubego Colon 38;
C  Grupa kontrolna, *p < 0.05 vs. C, ^p < 0.05 vs. FU 0.25 µg/ml
5Endokrynologia Polska/Polish Journal of Endocrinology 2007; (58) 1
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
(Fig. 2) of controls. Unexpectedly, leptin at the concen-
trations of 109 and 1010 M, applied jointly with fluoro-
uracil at lower concentrations, heightened the cytoto-
xic effect of fluorouracil (Fig. 2), but when fluorouracil
was given at a higher concentration it did not modula-
te the fluorouracil effect (Fig. 1).
Discussion
These data provide the first evidence that leptin may
reinforce the cytotoxic effect of fluorouracil on murine
Colon 38 cancer. Moreover, in our experimental model
leptin slightly but statistically significantly enhanced the
growth of Colon 38 cancer at most of the examined doses.
Its stimulatory effect was present in some concentrations:
106, 107 M and 1010, 1011, 1012 M but absent in the rest the
concentrations examined. The explanation of this diver-
gent and fluctuating effect of changed concentrations of
leptin and the lack of effect in the intermediate concentra-
tions (108 and 109 M) of this hormone may be the existen-
ce of two populations of leptin receptors involved in its
stimulatory action on the Colon 38 cancer cells examined.
So far only the long form of leptin receptor (ObR1) seems
to be the functional form [16, 17], whereas shorter isoforms
ubiquitously expressed on several tissues seem to be in-
volved in intra- and transcellular leptin transport [18] or
even in preventing the activation of ObR signalling in the
case of soluble leptin receptor (SLR) [19].
Since in our study the growth of Colon 38 cancer
was determined by the modified Mosmann method
based on the MTT assay, which reflects the number of
metabolically active cells, we concede that the growth
stimulatory effect of leptin observed should be interpre-
ted as the stimulation of cell proliferation or inhibition of
cell apoptosis or changes in both these processes. As we
know from other studies, leptin has stimulated the
growth of colon cancer cell lines mainly by means
of enhancement of cell proliferation [12, 14] and inhibi-
tion of apoptosis [12, 20].
Our data are in concordance with other observations
indicating the stimulatory effect of leptin on colon can-
cer growth and are in agreement with the hypothesis
that leptin is a risk factor for colon cancer. However,
our observations concerning a leptin-induced heighte-
ning of the cytotoxic effect of fluorouracil are in contra-
diction to this suggestion. It remains an open question
as to whether leptin is a favourable or unfavourable fac-
tor for colorectal carcinogenesis. Since leptin can mo-
dulate the cytotoxic effect of fluorouracil, the drug of
choice for patients with advanced colon cancer, we hy-
pothesise that leptin concentration in colon cancer pa-
tients should be taken into consideration in the adjust-
ment of fluorouracil doses in therapeutic protocol and
that doses of fluorouracil should be lower in obese pe-
ople. However, this will only be demonstrably true if
the synergistic effect of leptin and fluorouracil are ob-
served for human colon cancer.
These preliminary data call for further studies to elu-
cidate the exact role of leptin and the leptin-fluoroura-
cil interaction in colon cancer growth and therapy.
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Figure 2. The effect of leptin (L) applied alone or jointly with fluorouracil (FU) on the growth of Colon 38 cancer cells; C  Control,
*p < 0.05 vs C, ^p < 0.05 vs FU
Rycina 2. Wp‡yw leptyny (L) stosowanej oddzielnie lub w po‡„czeniu z fluorouracylem (FU) na wzrost komórek raka jelita grubego
Colon 38; C  Grupa kontrolna, *p < 0,05 vs. C, ^p < 0,05 vs. FU
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